Company Overview of Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors of viral replication enzymes that are essential to viral replication. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus, Influenza virus, Rhinovirus, Dengue Virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of various types, including non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepa...
19805 North Creek Parkway
Bothell, WA 98011
Founded in 2007
Key Executives for Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. does not have any Key Executives recorded.
Cocrystal Pharma, Inc. Key Developments
Cocrystal Pharma, Inc. Announces Executive Changes
Mar 12 15
Cocrystal Pharma, Inc. announced that due to medical reasons, Dr. Gary Wilcox will step down as the current Chief Executive Officer. Mr. Jeffrey Meckler has been appointed as the Interim Chief Executive Officer of the Company effective with the filing of the Form 10-K, later this month. Dr. Wilcox will become the Vice Chairman of the Board of Directors and continue as a senior advisor to the company. Mr. Meckler will continue as a Director of the Company, and Dr. Raymond F. Schinazi will become the Chairman of the Board. Mr. Meckler has over 25 years of experience in life science companies including 17 years at Pfizer Inc. in a variety of positions, including Manufacturing, Systems, Market Research and Corporate Finance. Mr. Meckler most recently was the Principal Executive Officer of QLT Inc.
Cocrystal Pharma, Inc. Files Amendment to its Certificate of Incorporation
Mar 3 15
On March 3, 2015, Cocrystal Pharma, Inc. filed an amendment to its Certificate of Incorporation with the Secretary of State of Delaware. This amendment increased the number of its authorized shares of common stock from 200,000,000 to 800,000,000. The amendment was effective upon filing. In accordance with the terms of the Certificate of Designation designating the Series A Preferred Stock and the Certificate of Incorporation designating the Series B Preferred Stock, immediately upon filing of the Certificate of Amendment to the company's Certificate of Incorporation, and without further action on the part of the holders, the Series A was converted into 340,760,802 shares of common stock and the Series B was converted into 205,083,086 shares of common stock.
Cocrystal Pharma, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 08:00 AM
Mar 3 15
Cocrystal Pharma, Inc. Presents at Barclays Global Healthcare Conference, Mar-12-2015 08:00 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Raymond F. Schinazi, Co-Chairman.
Similar Private Companies By Industry
Recent Private Companies Transactions